Content area

|
|

Vaccination til forebyggelse af meningokoksygdom

Forfatter(e)
Nanna Himmelstrup1, Cecilie Helkjær Engen1, Lars Østergaard2 & Thomas Lars Benfield1, 3 1) Infektionsmedicinsk Afdeling, Amager og Hvidovre Hospital2) Infektionsmedicinsk Afdeling, Aarhus Universitetshospital3) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ugeskr Læger 2019;181:V09180611
Reference: 
Ugeskr Læger 2019;181:V09180611
Sidetal: 

Nanna Himmelstrup, Cecilie Helkjær Engen, Lars Østergaard & Thomas Lars Benfield:

Vaccination for meningococcal disease

Ugeskr Læger 2019;181:V09180611

Neisseria meningiditis is a cause of sepsis and meningitis. Based on the capsule, six groups are recognised to cause invasive disease: A, B, C, W135, X and Y. In Denmark, five vaccines are marketed to protect against five of the six groups. One conjugated glycoprotein vaccine against serogroup C alone: MenC, two conjugated vaccines against ACWY: ACWY-TT/ACWY-CRM, and two protein-based vaccines against serogroup B: 4CMenB and MenB-fHbp. Overall, the efficacy is good, but the persistence of immunity is decreasing over time, why a booster is recommended for long-term protection.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Morten Holm | 24/03
17 kommentarer
af Astrid Hanna M. Schulze | 23/03
1 Kommentar
af Christian Schlütter | 23/03
10 kommentarer
af Poul Erik Rørbæk | 22/03
29 kommentarer
af Niels Foldager | 19/03
1 Kommentar
af Stig Gerdes | 18/03
4 kommentarer
af Gorm Greisen | 17/03
1 Kommentar
af Lars Erik Larsen | 17/03
5 kommentarer